Cue Biopharma, Inc. is a clinical stage biopharmaceutical company that develops injectable therapeutics designed to selectively engage and modulate disease specific T cells for the treatment of autoimmune inflammatory diseases and certain oncology indications. The company's ImmunoSTAT platform engineers biologics that harness transforming growth factor beta and interleukin 2 signaling to either promote regulatory T cell expansion or redirect antiviral T cells to deplete pathogenic cells. Its pipeline includes the CUE 400 series for autoimmune tolerance, the CUE 500 series for targeted B cell depletion, and the CUE 100 series for oncology focused T cell activation. Cue Biopharma, Inc. seeks to establish new standards of care through its modular approach and strategic collaborations. The lead candidate from the CUE 400 series, CUE 401, is a bifunctional fusion protein that combines a masked transforming growth factor beta with an attenuated interleukin 2 variant to induce regulatory T cells from effector T cells while expanding existing regulatory populations.
Cue Biopharma, Inc. generates revenue primarily through collaboration and license agreements with pharmaceutical partners that include upfront payments, milestone payments upon development and regulatory achievements, and royalties on future product sales. The company has entered into agreements with Boehringer Ingelheim International GmbH for the CUE 501 program, with ImmunoScape Pte. Ltd. for the CUE 100 series, with LG Chem Ltd. for certain territories of the CUE 101 and CUE 102 programs, and previously with Ono Pharmaceutical for CUE 401 rights. Additionally, the company receives royalty income under its license agreement with Albert Einstein College of Medicine for the use of its core ImmunoSTAT technology. These arrangements provide non dilutive funding that supports research and development activities while aligning incentives with partners who assume later stage development and commercialization responsibilities.
Cue Biopharma, Inc. occupies a niche in the immunotherapy market by focusing on selective T cell modulation rather than broad immune activation. Its ImmunoSTAT platform differentiates it from cytokine based therapies, bispecific antibodies, and cell therapies that often carry higher risks of systemic toxicity. Key competitors in the autoimmune cytokine space include Amgen, Bristol Myers Squibb, Merck and Company, Nektar Therapeutics, Sanofi SA, TRex Bio and RegCell. In the regulatory T cell therapy arena, competitors include Coya Therapeutics, Quell Therapeutics, EVOQ Therapeutics and Sonoma Biotherapeutics. The company's competitive advantages stem from its masked transforming growth factor beta and interleukin 2 design, which aims to reduce off target activity while promoting durable immune tolerance. Furthermore, the modular nature of the ImmunoSTAT framework allows the same core elements to be adapted for multiple disease areas, enhancing the potential for pipeline expansion and partnership opportunities.
Cue Biopharma, Inc. serves patients suffering from autoimmune inflammatory diseases and oncology indications through the therapeutic candidates developed by its partners. The company's direct customers are pharmaceutical and biotechnology firms that license its ImmunoSTAT technology, including Boehringer Ingelheim International GmbH, ImmunoScape Pte. Ltd., LG Chem Ltd., and Ono Pharmaceutical. These collaborations provide Cue Biopharma, Inc. with near term revenue through upfront and milestone payments while granting partners rights to develop and commercialize the licensed product candidates. In addition, the Einstein license generates ongoing royalty streams that contribute to the company's revenue base as its product candidates advance toward commercialization.